Dr. Geoffrey Shapiro on the Role of CDK2 in Multiple Breast Cancer Types

Geoffrey Shapiro, MD, PhD

Geoffrey Shapiro, MD, PhD, director, Early Drug Development Center, Dana Farber, discusses the role of cyclin-dependent kinase (CDK4) in some breast cancer subtypes and the lack of targeted agents in triple-negative breast cancer.

Geoffrey Shapiro, MD, PhD, director, Early Drug Development Center, Dana Farber, discusses the role of cyclin-dependent kinase (CDK4) in some breast cancer subtypes and the lack of targeted agents in triple-negative breast cancer. Shapiro says CDK4 plays a role in the proliferation of estrogen-receptor positive breast cancer and HER-2 positive breast cancer cells, though triple-negative breast cancer is still an enigma.